{
    "Trade/Device Name(s)": [
        "BGM Galectin-3",
        "BGM Galectin-3 TM"
    ],
    "Submitter Information": "BG Medicine, Inc.",
    "510(k) Number": "K093758",
    "Predicate Device Reference 510(k) Number(s)": [
        "K080269",
        "K052789",
        "K051787",
        "K033383",
        "K032235",
        "K030286",
        "K021317",
        "K010266",
        "K003475"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OSX"
    ],
    "Summary Letter Date": "November 3, 2010",
    "Summary Letter Received Date": "November 5, 2010",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.1117"
    ],
    "Regulation Name(s)": [
        "Test, Natriuretic Peptide"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "cardiac",
        "misc"
    ],
    "Analyte(s)": [
        "Galectin-3"
    ],
    "Specimen Type(s)": [
        "Serum",
        "EDTA-plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Serum tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Microtiter plate reader",
        "Spectrophotometer (plate reader)"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Colorimetric detection"
    ],
    "Methodologies": [
        "Sandwich ELISA",
        "Colorimetric analysis"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Quality control material",
        "Standard"
    ],
    "Document Summary": "FDA 510(k) summary for BGM Galectin-3 ELISA kit to quantitatively measure galectin-3 in serum or EDTA-plasma for prognosis assessment in chronic heart failure",
    "Indications for Use Summary": "Aids, in conjunction with clinical evaluation, in assessing the prognosis of patients diagnosed with chronic heart failure by quantitative measurement of galectin-3 in serum or EDTA-plasma",
    "fda_folder": "Clinical Chemistry"
}